ALKS (Alkermes plc) Stock Financials & Earnings | Market Cap Arena

ALKS (Alkermes plc) Stock Financials & Earnings | Market Cap Arena

ALKSAlkermes plc

Mkt Cap$5B

Healthcare·Biotechnology·🇮🇪 Ireland·NASDAQ

Revenue (TTM)$1.5B

Net Income (TTM)$242M

EPS (TTM)$1.43

Free Cash Flow (TTM)$480M

Gross Margin86.3%

Op. Margin17.2%

Net Margin16.4%

FCF Margin32.5%

P/S Ratio (TTM)3.2x

P/E Ratio (TTM)19.5x

YoY Rev Growth-5.2%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$288M	$229M	-$11M
Q2 23	$617M	$554M	$281M
Q3 23	$381M	$319M	$89M
Q4 23	$377M	$307M	$179M
Q1 24	$350M	$292M	$43M
Q2 24	$399M	$338M	$110M
Q3 24	$378M	$315M	$105M
Q4 24	$430M	$368M	$163M
Q1 25	$307M	$257M	$14M
Q2 25	$391M	$341M	$93M
Q3 25	$394M	$343M	$89M
Q4 25	$385M	$333M	$58M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	4.2x	—
Q2 23	3.2x	45.7x
Q3 23	3.0x	21.9x
Q4 23	2.8x	13.2x
Q1 24	2.7x	10.8x
Q2 24	3.1x	16.3x
Q3 24	3.1x	14.1x
Q4 24	3.0x	12.8x
Q1 25	3.1x	13.4x
Q2 25	3.1x	13.5x
Q3 25	3.1x	13.9x
Q4 25	3.2x	19.5x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$21M	-$28M
Q2 23	$216M	$206M
Q3 23	$100M	$85M
Q4 23	$107M	$90M
Q1 24	$21M	$13M
Q2 24	$146M	$139M
Q3 24	$82M	$73M
Q4 24	$190M	$181M
Q1 25	$99M	$89M
Q2 25	$150M	$137M
Q3 25	$102M	$84M
Q4 25	$170M	$170M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$7M
Q2 23	$10M
Q3 23	$14M
Q4 23	$17M
Q1 24	$8M
Q2 24	$7M
Q3 24	$8M
Q4 24	$10M
Q1 25	$10M
Q2 25	$13M
Q3 25	$17M
Q4 25	$20K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+3.2%	-2.2%
Q2 23	+123.5%	+8.2%
Q3 23	+51.0%	-6.8%
Q4 23	+23.9%	-38.8%
Q1 24	+21.8%	+2.8%
Q2 24	-35.4%	-13.9%
Q3 24	-0.7%	-6.3%
Q4 24	+13.9%	+34.4%
Q1 25	-12.5%	-4.7%
Q2 25	-2.1%	+2.9%
Q3 25	+4.2%	+11.6%
Q4 25	-10.6%	+22.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$21M	7.3%
Q2 23	$29M	4.6%
Q3 23	$24M	6.3%
Q4 23	$26M	6.8%
Q1 24	$33M	9.3%
Q2 24	$0	0.0%
Q3 24	$23M	6.0%
Q4 24	$21M	4.8%
Q1 25	$23M	7.4%
Q2 25	$25M	6.4%
Q3 25	$25M	6.3%
Q4 25	-$72M	-18.8%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$64M	$49M	$119M	—
Q2 23	$68M	$58M	$138M	—
Q3 23	$65M	$42M	$115M	—
Q4 23	—	$24M	$116M	—
Q1 24	$68M	$54M	$126M	—
Q2 24	$60M	$48M	$120M	—
Q3 24	$60M	$48M	$102M	—
Q4 24	$57M	$48M	$99M	—
Q1 25	$72M	$49M	$123M	—
Q2 25	$77M	$50M	$121M	—
Q3 25	$82M	—	—	$172M
Q4 25	$93M	—	—	$187M

Revenue Segments

Quarter	Manufactured Product And Royalty	Product
Q1 25	$62M	$244M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$321M	$279M	$600M
Q2 23	$666M	$163M	$829M
Q3 23	$648M	$241M	$889M
Q4 23	$457M	$316M	$773M
Q1 24	$421M	$324M	$745M
Q2 24	$535M	$341M	$876M
Q3 24	$396M	$513M	$909M
Q4 24	$291M	$461M	$752M
Q1 25	$400M	$484M	$884M
Q2 25	$521M	$495M	$1.0B
Q3 25	$616M	$495M	$1.1B
Q4 25	$588M	$200M	$788M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	165M	+0.5%
Q2 23	172M	+3.9%
Q3 23	172M	+0.2%
Q4 23	170M	-1.0%
Q1 24	173M	+1.7%
Q2 24	171M	-1.2%
Q3 24	167M	-2.3%
Q4 24	167M	-0.3%
Q1 25	169M	+1.3%
Q2 25	168M	-0.2%
Q3 25	169M	+0.1%
Q4 25	169M	+0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$476K	1K
FY 15	$419K	2K
FY 16	$426K	2K
FY 17	$452K	2K
FY 18	$476K	2K
FY 19	$524K	2K
FY 20	$463K	2K
FY 21	$531K	2K
FY 22	$488K	2K
FY 23	$792K	2K
FY 24	$865K	2K
FY 25	$15K	100K